A new executive order from President Trump requires federal agencies to design a 90-day strategy for splitting the MMR vaccine. This mandate seeks to provide parents with more choices by separating the measles, mumps, and rubella shots.
The five-year manufacturing hurdle for Merck and GSK
The shift toward unbundled vaccines faces a massive industrial and economic roadblock. According to the report, major pharmaceutical manufacturers,including Merck and GlaxoSmithKline (GSK), currently only produce the combination versions of these essential shots. Transitioning to individual preparations would require these companies to either revamp existting facilities or build entirely new production plants to accommodate the change.
This industrial overhaul is not a quick fix for the healthcare system. The source reports that such a transition typically takes five years or more and requires tens of millions of dollars in research and development.. Because both Merck and GSK have stated they stand by their existing combination shots and have no immediate plans to shift production, the federal mandate faces a significant gap between policy and industry capability .
Why six doctor visits could threaten immunization rates
Public health experts are expressing deep concern that increasing the number of required injections will lead to lower vaccination coverage. Under the current medical recommendations, children receive two doses of the MMR combo vaccine—one around their first birthday and a second after their fourth birthday. Under the new executive order,the measles component alone could potentially require six separate office visits for a single child.
Dr. Anna Durbin from the University of Maryland warns that this more burdensome and expensive vaccination schedule could inadvertently cause parents to miss critical immunization appointments. the increased logistical burden on families,combined with the potential for more frequent clinic visits, may actually decrease the overall rate of routine immunization .
Dr. Jesse Goodman’s demand for new scientific evidence
Beyond the logistical challenges, the scientific community is questioning the fundamental necessity of the move. Former FDA vaccine chief Dr. Jesse Goodman has stressed that there is currently no scientific evidence to support the benefit of dividing the MMR shot.
Dr. Goodman insists that for the unbundling to be medically justified, new studies must prove that split vaccines elicit immune responses that are equal to or better than the current combination shots. Furthermore, the Food and Drug Administration (FDA) would face an unprecedented regulatory task in evaluating each individual shot as a separate product, a process that could significantly slow down the approval of new vaccine iterations.
The absence of a commercial incentive for manufacturers
While the Trump administration claims that providing more injection options will boost public trust and coverage, several critical details remain unaddressed. It is currently unclear how the federal government intends to persuade a small number of manufacturers to invest heavily in a new regulatory pathway that offers no clear commercial benefit.
The report highlights a tension between parental convenience and public-health efficiency. Without a clear mechanism to incentivize the industry, the mandate may struggle to move past the planning stage. Furthermore, the administration has not yet addressed the risk that a more complex vaccination schedule could push certain diseases back into a foothold where they can thrive.
Comments 0